Kenvue Inc. will announce its second quarter 2026 financial results before the market opens on August 6, 2026. The company has decided not to host a quarterly conference call to review the results due to a pending transaction with Kimberly-Clark. The press release containing the financial details will be accessible on the company’s investor relations website.

Key Details

The announcement schedule provides investors with specific dates for accessing the quarterly performance data. The absence of a conference call is directly attributed to the ongoing transaction with Kimberly-Clark, which limits the company's ability to provide a live commentary on the results.

Accessing Information

Investors and stakeholders can view the official press release on the day of the announcement by visiting the company’s dedicated investor relations portal. The document will contain the comprehensive financial statements for the second quarter of 2026.

Kenvue Inc. is recognized as the world’s largest pure-play consumer health company by revenue. Its portfolio includes well-known brands such as Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol.

Barclays analyst Lauren Lieberman has maintained an Equal-Weight rating on Kenvue (NYSE: KVUE) and raised the price target to $19 from the previous $18. The revised target indicates a shift in the firm's valuation expectations for the consumer health company.

Rating and Price Target Details

The brokerage's decision to keep the rating at Equal-Weight suggests that while the stock's potential upside has increased, it still lacks a compelling catalyst for a Buy rating. The new price target of $19 represents a 5.5% increase from the prior target of $18.

The adjustment comes as market participants assess Kenvue's performance and strategic direction in the competitive consumer health sector.